Preliminary studies in laboratories indicate that two doses of the Pfizer / Biontech vaccine may not give sufficient protection against the variant ómicron of Coronavirus, but three doses are capable of neutralizing it.
The pharmaceutical firms, in a communiqué reported today, noted that a group of patients who had received two doses of the VACID-19 vaccine showed an effectiveness against the omicron variant 25 times lower than against the virus in their previous variant.
That "indicates that two doses of the BNTA162B2 vaccine may not be sufficient to protect against the infection with the omicron variant," said the statement.
But the preliminary data also indicate that "protection improves with a third dose of our vaccine," said Pfizer's president Albert Bourla.
"We are going to develop a specific vaccine against the omicron variant and we hope to have it available from here to March," they added in the statement.
For its part, Ugur Sahin, president of Biontech, declared that "the first data indicate that a third dose could offer a sufficient level of protection against the disease in any gravity degree caused by the omicron variant."
Omicron, considered "highly transmitable" by the World Health Organization (WHO), was detected for the first time at the end of November in South Africa and quickly identified in several countries, causing a panic wave, especially in Europe, where the Contages multiply.Date Of Update: 08 December 2021, 09:08